Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.

Identifieur interne : 008D83 ( Main/Exploration ); précédent : 008D82; suivant : 008D84

The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.

Auteurs : K D Ramaiah [Inde] ; P K Das ; P. Vanamail ; S P Pani

Source :

RBID : pubmed:14641843

Descripteurs français

English descriptors

Abstract

Lymphatic filariasis (LF) is targeted for global elimination. Transmission interruption through repeated annual single-dose mass administration of anti-filarial drugs is the mainstay of the LF elimination strategy. This study examined the ability of six rounds of mass administration of diethylcarbamazine (DEC) or ivermectin (IVM) to interrupt transmission of Wuchereria bancrofti by Culex quinquefasciatus, the predominant parasite and vector species, respectively. After six rounds of mass drug administration (MDA), received by 54-75% of the eligible population (> or =15 kg body weight), the resting vector infection and infectivity rates fell by 83% and 79% in the DEC arm, 85% and 84% in the IVM arm and 31% and 45% in the placebo arm, respectively. The landing vector infection and infectivity rates fell by 83% and 94% in the DEC arm, 63% and 75% in the IVM arm and 1% each in the placebo arm, respectively. The filarial larval load per resting mosquito declined by 92% and 93% and per landing mosquito by 83% and 69% in the DEC and IVM arms, respectively. The annual infective biting rate (AIBR) fell from 735 to 93 (87%) in the DEC arm, 422 to 102 (76%) in the IVM arm and 472 to 398 (16%) in the placebo arm. The annual transmission potential (ATP) declined from 2514 to 125 (95%), 1212 to 241 (80%) and 1547 to 1402 (9%) in the DEC, IVM and placebo arms, respectively. However, mosquitoes with infection [microfilaria/larva 1/larva 2 (Mf/L1/L2)] were found in all study villages. Three of five villages in the IVM arm and two of five in the DEC arm recorded no resting mosquitoes with infective-stage (L3) larva. Although the ATP, after six rounds of MDA, fell substantially and remained at 125 and 241 in the DEC and IVM arms, respectively, the cumulative exposure to infective stage larvae (ATP) during the treatment period of 6 years was as high as 2995 in the DEC arm and 1522 in the IVM arm, because of considerable level of transmission during the initial (1-3) rounds of MDA. We conclude that (i) six rounds of MDA, even with 54-75% treatment coverage, can reduce LF transmission very appreciably; (ii) better treatment coverage and a few more rounds of MDA may achieve total interruption of transmission; (iii) high vector densities may partly nullify the reductions achieved in vector infection and infectivity rates by MDA and (iv) achievement of 'true zero' Mf prevalence in communities and 0% infection rate (mosquitoes with Mf/L1/L2) in mosquitoes may be necessary to totally interrupt Culex-transmitted LF.

PubMed: 14641843


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.</title>
<author>
<name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K D" last="Ramaiah">K D Ramaiah</name>
<affiliation wicri:level="1">
<nlm:affiliation>Vector Control Research Centre, Indian Council of Medical Research, Indira Nagar, Pondicherry, India. ramaiahk@yahoo.com</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Indian Council of Medical Research, Indira Nagar, Pondicherry</wicri:regionArea>
<wicri:noRegion>Pondicherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
</author>
<author>
<name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name>
</author>
<author>
<name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14641843</idno>
<idno type="pmid">14641843</idno>
<idno type="wicri:Area/PubMed/Corpus">004127</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004127</idno>
<idno type="wicri:Area/PubMed/Curation">004127</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004127</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004127</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004127</idno>
<idno type="wicri:Area/Ncbi/Merge">001760</idno>
<idno type="wicri:Area/Ncbi/Curation">001760</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001760</idno>
<idno type="wicri:doubleKey">1360-2276:2003:Ramaiah K:the:impact:of</idno>
<idno type="wicri:Area/Main/Merge">009054</idno>
<idno type="wicri:Area/Main/Curation">008D83</idno>
<idno type="wicri:Area/Main/Exploration">008D83</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.</title>
<author>
<name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K D" last="Ramaiah">K D Ramaiah</name>
<affiliation wicri:level="1">
<nlm:affiliation>Vector Control Research Centre, Indian Council of Medical Research, Indira Nagar, Pondicherry, India. ramaiahk@yahoo.com</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Indian Council of Medical Research, Indira Nagar, Pondicherry</wicri:regionArea>
<wicri:noRegion>Pondicherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
</author>
<author>
<name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name>
</author>
<author>
<name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name>
</author>
</analytic>
<series>
<title level="j">Tropical medicine & international health : TM & IH</title>
<idno type="ISSN">1360-2276</idno>
<imprint>
<date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Culex (parasitology)</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Elephantiasis, Filarial (parasitology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Elephantiasis, Filarial (transmission)</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (therapeutic use)</term>
<term>Humans</term>
<term>Insect Vectors (parasitology)</term>
<term>Ivermectin (administration & dosage)</term>
<term>Ivermectin (therapeutic use)</term>
<term>Rural Health</term>
<term>Wuchereria bancrofti (drug effects)</term>
<term>Wuchereria bancrofti (isolation & purification)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Calendrier d'administration des médicaments</term>
<term>Culex (parasitologie)</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Filaricides (administration et posologie)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (parasitologie)</term>
<term>Filariose lymphatique (transmission)</term>
<term>Humains</term>
<term>Ivermectine (administration et posologie)</term>
<term>Ivermectine (usage thérapeutique)</term>
<term>Méthode en double aveugle</term>
<term>Santé en zone rurale</term>
<term>Vecteurs insectes (parasitologie)</term>
<term>Wuchereria bancrofti ()</term>
<term>Wuchereria bancrofti (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en">
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr">
<term>Culex</term>
<term>Filariose lymphatique</term>
<term>Vecteurs insectes</term>
</keywords>
<keywords scheme="MESH" qualifier="parasitology" xml:lang="en">
<term>Culex</term>
<term>Elephantiasis, Filarial</term>
<term>Insect Vectors</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
<term>Filariose lymphatique</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Humans</term>
<term>Rural Health</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Calendrier d'administration des médicaments</term>
<term>Filariose lymphatique</term>
<term>Humains</term>
<term>Méthode en double aveugle</term>
<term>Santé en zone rurale</term>
<term>Wuchereria bancrofti</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Lymphatic filariasis (LF) is targeted for global elimination. Transmission interruption through repeated annual single-dose mass administration of anti-filarial drugs is the mainstay of the LF elimination strategy. This study examined the ability of six rounds of mass administration of diethylcarbamazine (DEC) or ivermectin (IVM) to interrupt transmission of Wuchereria bancrofti by Culex quinquefasciatus, the predominant parasite and vector species, respectively. After six rounds of mass drug administration (MDA), received by 54-75% of the eligible population (> or =15 kg body weight), the resting vector infection and infectivity rates fell by 83% and 79% in the DEC arm, 85% and 84% in the IVM arm and 31% and 45% in the placebo arm, respectively. The landing vector infection and infectivity rates fell by 83% and 94% in the DEC arm, 63% and 75% in the IVM arm and 1% each in the placebo arm, respectively. The filarial larval load per resting mosquito declined by 92% and 93% and per landing mosquito by 83% and 69% in the DEC and IVM arms, respectively. The annual infective biting rate (AIBR) fell from 735 to 93 (87%) in the DEC arm, 422 to 102 (76%) in the IVM arm and 472 to 398 (16%) in the placebo arm. The annual transmission potential (ATP) declined from 2514 to 125 (95%), 1212 to 241 (80%) and 1547 to 1402 (9%) in the DEC, IVM and placebo arms, respectively. However, mosquitoes with infection [microfilaria/larva 1/larva 2 (Mf/L1/L2)] were found in all study villages. Three of five villages in the IVM arm and two of five in the DEC arm recorded no resting mosquitoes with infective-stage (L3) larva. Although the ATP, after six rounds of MDA, fell substantially and remained at 125 and 241 in the DEC and IVM arms, respectively, the cumulative exposure to infective stage larvae (ATP) during the treatment period of 6 years was as high as 2995 in the DEC arm and 1522 in the IVM arm, because of considerable level of transmission during the initial (1-3) rounds of MDA. We conclude that (i) six rounds of MDA, even with 54-75% treatment coverage, can reduce LF transmission very appreciably; (ii) better treatment coverage and a few more rounds of MDA may achieve total interruption of transmission; (iii) high vector densities may partly nullify the reductions achieved in vector infection and infectivity rates by MDA and (iv) achievement of 'true zero' Mf prevalence in communities and 0% infection rate (mosquitoes with Mf/L1/L2) in mosquitoes may be necessary to totally interrupt Culex-transmitted LF.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Inde</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
<name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name>
<name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name>
</noCountry>
<country name="Inde">
<noRegion>
<name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K D" last="Ramaiah">K D Ramaiah</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008D83 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008D83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:14641843
   |texte=   The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:14641843" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024